INTRODUCTION
============

During the short period of approximately 3 months since coronavirus disease 2019 (COVID-19) was first reported in the city of Wuhan, Hubei Province, China at the end of December 2019, this disease became a pandemic, with large-scale outbreaks in China, South Korea, Iran, and Europe \[[@b1-ceo-2020-00570]-[@b4-ceo-2020-00570]\]. Although the World Health Organization declared COVID-19 to be a public health emergency of international concern on January 30, 2020 \[[@b5-ceo-2020-00570]\], the number of patients diagnosed with COVID-19 in Europe, the United States, and South America exploded in March 2020 \[[@b6-ceo-2020-00570],[@b7-ceo-2020-00570]\]. The reproductive number of COVID-19 estimated from previously reported studies, representing the average number of new patients infected by a patient in a naïve population, is over 3, which is considerably higher than those of severe acute respiratory syndrome and Middle East respiratory syndrome (MERS) \[[@b8-ceo-2020-00570],[@b9-ceo-2020-00570]\].

COVID-19 is mainly diagnosed by using real-time reverse transcription-polymerase chain reaction (rRT-PCR) to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in samples obtained through nasopharyngeal or oropharyngeal swabs \[[@b10-ceo-2020-00570]-[@b13-ceo-2020-00570]\]. Although rRT-PCR for COVID-19 was initially developed within 2 weeks after the emergence of the disease, this test cannot be performed on all suspected patients because COVID-19 has rapidly spread beyond the capacity for testing \[[@b14-ceo-2020-00570]\]. Thus, proper screening for the disease and isolation of suspected patients performed by the physicians and healthcare providers who first come into contact with them is the most important step in controlling this highly infectious disease, meaning that awareness and knowledge of the clinical features of COVID-19 are necessary for physicians and health-care providers \[[@b15-ceo-2020-00570]\]. The most common symptom in patients diagnosed with COVID-19 is known to be fever, which is frequently accompanied by coughing or difficulty in breathing \[[@b16-ceo-2020-00570],[@b17-ceo-2020-00570]\]. However, some COVID-19 patients demonstrate no symptoms or complain of only gastrointestinal (GI) symptoms; furthermore, the clinical features of COVID-19 patients diagnosed outside of Wuhan, China differed from those of patients diagnosed in Wuhan \[[@b18-ceo-2020-00570]\]. Therefore, additional diagnostic clues for COVID-19 have been investigated; promisingly, chest computed tomography (CT) has recently been reported to detect lung changes caused by COVID19 before the occurrence of symptoms \[[@b19-ceo-2020-00570],[@b20-ceo-2020-00570]\].

Within only 2 months since the first report of COVID-19, hundreds of reports related to COVID-19 have been published in reputable scientific journals. At this point, it is impossible to conduct a randomized clinical trial or a well-designed prospective study on the diagnosis and treatment of COVID-19, as only a short time has passed since this new disease emerged. Proportion meta-analysis is a statistical technique that provides integrated information in the absence of studies with a high level of evidence \[[@b21-ceo-2020-00570]-[@b24-ceo-2020-00570]\]. It should be kept in mind that this technique provides a relatively low level of evidence compared to other types of meta-analysis, as it generates results from studies with low levels of evidence, such as case series or observational studies \[[@b23-ceo-2020-00570]\]. However, this technique is expected to provide more integrated information about COVID-19 for health-care providers than is provided by extant studies in isolation.

Since the first report in Wuhan, the medical environment surrounding COVID-19 has undergone many changes, including increased awareness of the disease and the dissemination of diagnostic kits. Thus, it is expected that there will be changes in the clinical features of patients diagnosed with COVID-19, and identifying such differences will help health-care providers better understand and diagnose this disease. The objectives of this study were to identify the clinical features and chest CT findings of COVID-19 patients and to compare the characteristics of patients diagnosed in Wuhan and in other areas by integrating the findings reported in previous studies.

MATERIALS AND METHODS
=====================

Protocol of the study
---------------------

This study was conducted under the recommendations of Reporting Items for Systematic Reviews and Meta-Analyses. This study was performed by two teams for rapid review, one team was in charge of the survey and collection of included studies, and the other team was in charge of quality assessment of the included studies. Each team consisted of two main reviewers and a supervisor who adjusted the disagreements of the review results. For rapid review considering the urgency of a target disease for analysis, all types of the article what identified in the online databases were considered as candidates for inclusion in the study.

Survey of literature and inclusion of studies for analysis
----------------------------------------------------------

On March 17, 2020, two reviewers (YSL and WJ) searched the online databases of the U.S. National Library of Medicine (Medline) and Excerpta Medica (Embase) for identifying reports published in English that used the terms: COVID-19; SARS-Cov-2; and Novel coronavirus 2019. The titles, abstracts, and authors' information were saved into excel files, and later screened by two reviewers. All type of reports in the English language that contained the descriptions of clinical features and CT findings except for the review articles were included in a data-set for detailed review, and two reviewers included only studies with data on four or more patients (case-series, cohort, or observational study) into the data-set to provide a higher level of evidence \[[@b25-ceo-2020-00570]\]. Published editorials and letters to editors were also considered as candidates for the study to a maximum extent possible. In the review process (the assessments of study eligibility), to minimize the risk of duplicating data in this analysis \[[@b26-ceo-2020-00570]\], only the largest study was included if the duration of patient inclusion overlapped among reports from the same hospital. If data were reported from the same hospital without information about the date of patient inclusion, this study was also eventually excluded. All data were collected using identical forms to minimize the variability of reviewers, and disagreements of in the review results were adjusted by the third reviewer (JL).

Data collection and quality assessment
--------------------------------------

The extraction of data from included studies was independently conducted by two reviewers. Name of the first author, the origin of reports including hospital and province, the initial date of patient inclusion, and the number of patients included were recorded in the Microsoft Excel database. Demographic data, symptoms of patients, and chest CT findings were extracted. The results were categorized into the regions where COVID-19 patients were diagnosed as follows: Wuhan, outside of Wuhan in China, and other country groups. Quality assessments of included studies were independently performed by two reviewers (professors of college of medicine, CGC and SWP), who did not participate in the data review process, using a quality assessment tool for case-series study from the National Institutes of Health, which consisted of nine questions ([Supplementary Table 1](#SD1-ceo-2020-00570){ref-type="supplementary-material"}) \[[@b27-ceo-2020-00570]\]. The disagreements in the quality assessment were also discussed by a third reviewer (JL). The results of the quality assessment were represented in a fair, good, and poor grouping to assist in the understanding of this study.

Statistical analysis
--------------------

Proportion meta-analysis was conducted to determine the clinical features and chest CT findings of COVID-19 patients; subsequently, clinical and chest CT characteristics of patients were compared after the areas diagnosed with COVID-19 were classified as Wuhan, outside of Wuhan in China, and other countries. We used a random-effect model provided by MedCalc statistical software due to the presence of uncontrolled variables of included studies. All results were represented as a forest plot with the horizontal bar corresponding to the 95% confidence interval (CI) of the effect estimates, and overlap of 95% CI was defined as the absence of difference among the groups in the comparative analysis \[[@b28-ceo-2020-00570]\]. I2 test and Cochran Q were used for evaluating heterogeneities of the results belonging to analysis. I2 lied between 0% to 100% and additional descriptions were made if they complied with the criteria described as follows: low (\<40%), moderate (30%--60%), and considerable (75%--100%), retrospectively \[[@b29-ceo-2020-00570]\]. This parameter stated the percentage of variability in effect estimates calculated from heterogeneity. Cochran Q test is the parameter computed by summing squared deviations of the estimate of each study, and the parameter of \<0.10 determined the heterogeneity \[[@b30-ceo-2020-00570]\]. Although we described these two parameters for measuring heterogeneity, I2 which is not affected by the number of included studies for meta-analysis was considered as a more appropriate parameter for the evaluation of heterogeneity in this study \[[@b30-ceo-2020-00570]\]. The publication bias among included studies was determined when the *P*-value was \<0.05 on Egger's regression test \[[@b31-ceo-2020-00570]\]. Forest plot calculated by MedCalc was redrawn using Microsoft Excel program (Microsoft, Redmond, WA, USA) for easy interpretation of figure \[[@b32-ceo-2020-00570]\]. Chi-square test was used to compare the compositions of gender among groups.

RESULTS
=======

Data extraction from included studies and quality assessment
------------------------------------------------------------

In total, 783 abstracts and titles were identified and screened, and 102 abstracts were excluded in this step as they were not written in English. Additionally, abstracts presenting clinical features and chest CT findings from four or fewer patients were excluded. Eighty-seven reports were completely reviewed, and studies that were likely to present duplicate patient data were also excluded. Finally, nine studies (four studies reporting findings from Wuhan and five studies reporting findings from outside of Wuhan in China) with level IV evidence (case series, observational studies, or cohort studies) were eligible for the meta-analysis ([Fig. 1](#f1-ceo-2020-00570){ref-type="fig"}) \[[@b33-ceo-2020-00570]-[@b41-ceo-2020-00570]\]. As only one study each from South Korea and Europe described the clinical features and chest CT findings of patients from outside China, a comparative analysis was only possible between patients diagnosed in Wuhan and outside of Wuhan in China. Information about 627 patients (male, 345; female, 282) diagnosed with COVID-19 was obtained from nine studies ([Table 1](#t1-ceo-2020-00570){ref-type="table"}). However, it was not possible to consistently present the mean or median age of the included patients because five studies reported age as a median value and four studies reported age as a mean value. There was no significant difference in the sex ratio between the two groups (*P*=0.157) upon chisquare analysis. Among the clinical features described in the included studies, fever, cough, sputum, dyspnea, myalgia, fatigue, and GI symptoms were available for meta-analysis and comparisons ([Table 2](#t2-ceo-2020-00570){ref-type="table"}). Comparisons of chest CT findings were possible for pathologic findings (ground-glass opacity \[GGO\] and consolidation) and the distribution of abnormal findings (single lobe, multiple lobes, and both lungs) ([Table 3](#t3-ceo-2020-00570){ref-type="table"}). Laboratory findings (leukocytosis, leukopenia, and decreased lymphocyte count) could also be analyzed, as demonstrated in [Supplementary Table 2](#SD2-ceo-2020-00570){ref-type="supplementary-material"}.

Clinical features
-----------------

COVID-19 was diagnosed despite the absence of symptoms in 4.1% of the patients (9/242) from outside of Wuhan ([Table 2](#t2-ceo-2020-00570){ref-type="table"}). Fever (84.8%; 95% CI, 78.5% to 90.1%; I^2^=73.6%) was the most common symptom of COVID-19, followed by cough (52.0%; 95% CI, 34.1% to 69.7%; I^2^=95.0%) ([Fig. 2A](#f2-ceo-2020-00570){ref-type="fig"} and [B](#f2-ceo-2020-00570){ref-type="fig"}). Sputum and dyspnea were only present in 21.3% (95% CI, 17.2% to 25.7%; I^2^=0%) and 10.4% (95% CI, 2.0% to 24.5%; I^2^=88.87%) of patients, respectively ([Fig. 2C](#f2-ceo-2020-00570){ref-type="fig"}). Myalgia and fatigue were present in 27.3% (95% CI, 16.6% to 39.4%; I^2^=87.6%) and 16.7% (95% CI, 10.4% to 24.2%; I^2^=72.5%) of patients, respectively. GI symptoms were reported by 11.6% (95% CI, 7.7% to 16.1%; I^2^=54.6%) of patients ([Fig. 2D](#f2-ceo-2020-00570){ref-type="fig"}).

In a comparison of symptoms between the patients diagnosed in Wuhan and outside of Wuhan, fever was more frequently observed in the patients diagnosed in Wuhan (91.7%; 95% CI, 88.0% to 94.8%; I^2^=17.94%) than in those diagnosed outside of Wuhan (78.1%; 95% CI, 73.2% to 82.7%; I^2^=0%) ([Fig. 3A](#f3-ceo-2020-00570){ref-type="fig"}). However, the proportion of patients with cough was similar between the Wuhan (41.3%; 95% CI, 8.2% to 79.9%; I^2^=97.9%) and non-Wuhan groups (59.4%; 95% CI, 47.8% to 70.4%; I^2^=71.2%). Similar to fever, dyspnea was significantly more frequent in the patients diagnosed in Wuhan (21.1%; 95% CI, 13.2% to 30.3%; I^2^=11.0%) than in those diagnosed outside of Wuhan (3.80%; 95% CI, 0.13% to 12.22%; I^2^=74.75%) ([Fig. 3B](#f3-ceo-2020-00570){ref-type="fig"}). However, no significant difference was observed in the frequency of sputum between the Wuhan group (23.33%; 95% CI, 18.1% to 29.1%; I^2^=0%) and the non-Wuhan group (17.7%; 95% CI, 11.5% to 24.9%; I^2^=0%).

Chest CT findings
-----------------

The chest CT findings of the included studies are presented in [Table 3](#t3-ceo-2020-00570){ref-type="table"}. A GGO pattern and consolidation were observed in 66.76% (95% CI, 52.56% to 79.55%; I^2^=90.35%) and 35.15% (95% CI, 20.96% to 50.84%; I^2^=92.02%) of COVID-19 patients, respectively ([Fig. 4](#f4-ceo-2020-00570){ref-type="fig"}). The most common distribution of pathologic findings was involvement of multiple lobes (81.21%; 95% CI, 69.73% to 90.46%; I^2^=86.10%), while only 14.47% (95% CI, 4.99% to 28.27%; I^2^=91.82%) of patients had pathologic findings distributed in a single lobe ([Fig. 5](#f5-ceo-2020-00570){ref-type="fig"}). Bilateral lung involvement was identified in 80.41% (95% CI, 71.75% to 87.81%; I^2^=81.84%) of patients. No significant difference was observed in the frequency of patients in whom the pathologic findings showed only single-lobe involvement between the Wuhan group (11.09%; 95% CI, 5.71% to 17.96%; I^2^=32.20%) and the nonWuhan group (17.77%; 95% CI, 2.22% to 43.56%; I^2^=95.59%). The distribution of multiple-lobe and bilateral lung involvement was similar in both groups. The results of the comparison of the proportions of chest CT findings between the groups are presented in [Supplementary Figs. 1](#SD3-ceo-2020-00570){ref-type="supplementary-material"} and [2](#SD4-ceo-2020-00570){ref-type="supplementary-material"}.

DISCUSSION
==========

Within only 3 months after it was first reported in China, the COVID-19 pandemic has spread to South Korea, Iran, Italy, and the United States, and the number of patients worldwide has rapidly increased \[[@b6-ceo-2020-00570],[@b7-ceo-2020-00570]\]. Since COVID-19 is estimated to be more infectious than MERS and more fatal than influenza, physicians and health-care providers should actively work to diagnose COVID-19 and to keep COVID-19 patients in isolation to minimize the spread of the disease and prevent deterioration of the current situation. Although COVID-19 is diagnosed using rRT-PCR tests, proper screening conducted by health-care providers is the most important prerequisite for controlling the spread of COVID-19, as diagnostic capacity and accessibility of medical care differ from country to country \[[@b15-ceo-2020-00570],[@b42-ceo-2020-00570]\].

Patients' symptoms are important clues for the diagnosis of a disease, and the same is true for the screening of diseases \[[@b15-ceo-2020-00570]\]. Essentially, all the relevant guidelines recommend that symptoms and epidemiological risk (history of contact with COVID-19 patients and history of visits to pandemic-affected areas) should be considered as part of COVID-19 screening \[[@b7-ceo-2020-00570],[@b12-ceo-2020-00570],[@b43-ceo-2020-00570],[@b44-ceo-2020-00570]\]. According to the Centers for Disease Control and Prevention, screening for COVID-19 should be based on the presence of symptoms of fever, cough, and shortness of breath \[[@b12-ceo-2020-00570]\]. The most common symptom in patients diagnosed with COVID-19 was fever (84.8%; 95% CI, 78.5% to 90.1%; I^2^=73.6%), which was frequently accompanied by cough (52.0%; 95% CI, 34.1% to 69.7%; I^2^=95.0%). In addition, 21.3% and 10.4% of patients complained of sputum and dyspnea (other signs of respiratory infection). Moreover, myalgia (27.3%) and fatigue (16.7%), which are symptoms of inflammation due to SARS-CoV-2, were also less common than fever and cough. Although all of symptoms mentioned above, except sputum, exhibited significant heterogeneity, fever accompanied by the signs of a respiratory infection can be considered as a reasonable parameter for suspecting COVID-19, especially in patients with epidemiological risk, as has been recommended by many guidelines \[[@b7-ceo-2020-00570],[@b12-ceo-2020-00570],[@b43-ceo-2020-00570],[@b44-ceo-2020-00570]\]. Interestingly, over 10% of patients in the present study complained of GI symptoms. GI symptoms are thought to be a characteristic of SARSCoV-2 infection, especially in light of the previous finding that over 30% of MERS patients complained of GI symptoms \[[@b45-ceo-2020-00570]\]. Recently, olfactory and gustatory dysfunction as determined by a questionnaire evaluation has been observed in 85% of mildto-moderate COVID-19 patients in Europe; the reported frequency of this symptom is therefore similar to that of fever and higher than that of cough in the present study \[[@b46-ceo-2020-00570]\]. Thus, physicians, especially otorhinolaryngologists, should be aware of these symptoms, in addition to fever accompanied by the signs of respiratory infection, as a possible clinical presentation of COVID-19. Olfactory and gustatory complaints were the initial symptoms in approximately 15% of COVID-19 patients, and 11.8% of patients complained of only olfactory changes without other nasal symptoms \[[@b46-ceo-2020-00570]\]. However, we could not find any information on these symptoms in the studies included in this meta-analysis. The patients included in this study were mainly diagnosed with COVID-19 in January 2020, not long after the emergence of COVID-19. Since these diagnoses were made in the early phase of COVID-19 transmission, a lack of awareness of olfactory/gustatory dysfunction, as well as differences in disease severity in patients depending on the time of COVID-19 diagnosis, may explain why information on these symptoms was missing in the included studies. Although the results of this study did not address olfactory or gustatory dysfunctions observed in COVID-19 patients, based on current knowledge, otorhinolaryngologists must consider the possibility of COVID-19 if patients with epidemiological risk of this disease complain of olfactory or gustatory dysfunction.

Fever is known to occur in a relatively early phase of COVID19, whereas dyspnea is a symptom that generally occurs in the rapid progression phase, which takes place 3 to 7 days after the onset of symptoms \[[@b44-ceo-2020-00570]\]. The present meta-analysis revealed that fever and dyspnea were less frequent in the patients diagnosed outside of Wuhan than in those diagnosed in Wuhan. In addition, asymptomatic COVID-19 patients were only reported in the non-Wuhan group. In a report from South Korea, among a total of 28 patients, three patients without symptoms (10.71%) were diagnosed with COVID-19, and only 32.14% of patients (9/28) complained of fever \[[@b47-ceo-2020-00570]\]. This trend was also observed in a study reporting the clinical features of 38 COVID-19 patients in Europe; 5.26% of patients (2/38) were asymptomatic and fever was observed in only 52.63% (20/38) \[[@b48-ceo-2020-00570]\]. Most studies of both groups (the Wuhan group and the non-Wuhan group) in this meta-analysis included patients diagnosed in a similar period. Since the initial outbreak of COVID-19 is assumed to have occurred in Wuhan, the interval between infection and COVID-19 diagnosis is thought to have been shorter in the non-Wuhan group than in the Wuhan group. Thus, the lower frequency of fever and the higher number of asymptomatic patients observed outside of Wuhan is thought to be due to the early diagnosis of COVID-19 as a consequence of physicians' increased awareness of the disease and epidemiological assessments of high-risk individuals. Although it was not practicable to conduct a meta-regression analysis of the effect of age on clinical manifestations because of variation in how age was reported in the included studies, the patients from outside of Wuhan seemed to be younger than the patients diagnosed in Wuhan. Since the clinical manifestations and disease severity of COVID-19 vary depending on age \[[@b38-ceo-2020-00570]\], these results should be interpreted with caution, in light of the possibility that the age difference between the groups may have affected the differences in clinical manifestations found in this study.

Regarding disease screening, we still should be aware that fever and dyspnea were less frequent in patients diagnosed outside of Wuhan in China. It is apparent that only using symptoms as screening criteria for COVID-19 results in an increased chance of failure of early diagnosis of COVID-19 in actual patients. Therefore, the assessment of epidemiological risk is of prime importance in patients complaining of fever accompanied by signs of respiratory infection. If it is not possible to conduct rRT-PCR for COVID-19 in high-risk individuals, proper isolation of these patients for 2 weeks to minimize their contact with other people around them---even if they do not have symptoms or their symptoms are minor---is necessary considering the incubation period of COVID-19 \[[@b43-ceo-2020-00570]\]. In addition, it would be preferable to have a monitoring system for identifying patients' history of visits to pandemic-affected areas and for keeping track of high-risk individuals through government interventions with the purpose of controlling this infectious disease.

Numerous studies have reported the radiologic findings of COVID-19 patients. While simple chest radiography plays a limited role in COVID-19 screening, chest CT is known to detect lung abnormalities, single or focal GGO patterns, the presence of a nodule in the central lobule, and patchy consolidation even before the onset of symptoms because of its high resolution \[[@b34-ceo-2020-00570],[@b40-ceo-2020-00570],[@b44-ceo-2020-00570]\]. GGO is an initial pathologic finding that can be observed in the lungs even before symptom onset, whereas the consolidation pattern is a relatively late finding in the progression of COVID-19 \[[@b44-ceo-2020-00570]\]. These pathologic findings gradually involve bilateral and multiple lobes during the course of disease progression. Although we assumed that COVID-19 was diagnosed earlier in the non-Wuhan group, no significant betweengroup differences were found in the distribution of patterns involving a single lobe, multiple lobes, and the bilateral lungs. The results regarding GGO and consolidation are similar to results reported from South Korea (GGO, 8/9; consolidation, 2/9) \[[@b49-ceo-2020-00570]\]. Since all five parameters reflecting chest CT findings exhibited considerable heterogeneity in the results extracted from the included studies, the present study does not provide support for any conclusions regarding the role of chest CT in COVID-19 screening.

This study has several limitations and the results should be interpreted with caution. First, the results of this study can only serve as the basis for weak recommendations because of the low level of evidence of the included studies, the small number of patients, and methodological limitations \[[@b24-ceo-2020-00570]\]. Second, there was considerable heterogeneity in the results of the included studies. It is hypothesized that these outcomes could reflect differences between the groups. Third, it is possible that this study did not include exhaustive information about COVID-19, as case reports and studies with insufficient information were excluded from the present analysis to increase the level of evidence.

In conclusion, fever accompanied by signs of respiratory infection is considered to be the most reliable manifestation of COVID-19. Fever and dyspnea were observed less frequently in patients diagnosed outside of Wuhan in China, which should be considered in COVID-19 screening. Regional differences in the proportion of symptoms may be attributable to the earlier diagnosis of the disease and the younger age of the patients outside of Wuhan although further analysis is needed. Finally, the results of this study do not support any specific conclusions regarding the role of chest CT in diagnosing COVID-19.

HIGHLIGHTS
==========

▪ Fever was found to be the most common clinical manifestation in all coronavirus disease 2019 (COVID-19) patients.

▪ Fever and dyspnea were less frequent in patients diagnosed outside of Wuhan than in those diagnosed in Wuhan, which may be attributable to the earlier diagnosis of the disease and the younger age of patients outside of Wuhan.

▪ Since there were no significant differences in pathologic patterns and their distribution on chest computed tomography (CT) between the patients diagnosed in Wuhan and outside of Wuhan, the role of chest CT in the diagnosis of COVID-19 is inconclusive based on this study.
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Quality assessment tool for case series studies provided by the National Institutes of Health

###### 

The proportion of laboratory findings in patients with COVID-19

###### 

Comparison of proportion of chest computed tomography findings between Wuhan and outside of Wuhan in China \[[@b33-ceo-2020-00570]-[@b41-ceo-2020-00570]\]. The proportions in ground-glass opacity (GGO; A) and consolidation (B). CI, confidence interval.

###### 

Comparison of proportion of pathologic finding distribution between Wuhan and outside of Wuhan in China \[[@b33-ceo-2020-00570]-[@b41-ceo-2020-00570]\]. The proportions in single lobe involvement (A), multiple lobe involvement (B), and bilateral lungs involvement (C). CI, confidence interval.

![Flowchart of the final inclusion of studies. Nine studies were found to be eligible for the meta-analysis \[[@b33-ceo-2020-00570]-[@b41-ceo-2020-00570]\], extracted from 783 abstracts and titles.](ceo-2020-00570f1){#f1-ceo-2020-00570}

![The proportions of symptoms in coronavirus disease 2019 (COVID-19) patients extracted from nine studies \[[@b33-ceo-2020-00570]-[@b41-ceo-2020-00570]\]. The proportions of fever (A), cough (B), dyspnea (C), and gastrointestinal symptoms (D). CI, confidence interval.](ceo-2020-00570f2){#f2-ceo-2020-00570}

![Comparison of the proportions of symptoms between patients diagnosed in Wuhan and outside of Wuhan in China \[[@b33-ceo-2020-00570]-[@b41-ceo-2020-00570]\]. Significant differences were noted in the proportion of patients with fever (A) and dyspnea (B). CI, confidence interval.](ceo-2020-00570f3){#f3-ceo-2020-00570}

![The proportions of pathologic patterns observed on chest computed tomography (CT) in patients with coronavirus disease 2019 (COVID-19) \[[@b33-ceo-2020-00570]-[@b41-ceo-2020-00570]\]. The proportions of patients with ground-glass opacity (A) and consolidation (B). GGO, ground-glass opacity; CI, confidence interval.](ceo-2020-00570f4){#f4-ceo-2020-00570}

![The proportions of the distribution of pathologic findings observed on chest computed tomography in patients with coronavirus disease 2019 (COVID-19) \[[@b33-ceo-2020-00570]-[@b41-ceo-2020-00570]\]. The proportions of single lobe involvement (A), multiple lobe involvement (B), and bilateral lung involvement (C). CI, confidence interval.](ceo-2020-00570f5){#f5-ceo-2020-00570}

###### 

Brief information about the included studies

  First author                      Hospital                              Province             Level of evidence   Date of patients' inclusion   No. of patients   Outcome    Quality assessment                                                          
  --------------------------------- ------------------------------------- -------------------- ------------------- ----------------------------- ----------------- ---------- -------------------- ----- ----- ----- ----- ----- ----- ----- ----- ------ ------
  Wuhan                                                                                                                                          338                                                                                                      
                                    Zhou \[[@b33-ceo-2020-00570]\]        Jinyintan Hospital   Hubei               IV                            01/16/2020        191        S, CT, L             Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes    Good
  Wuhan Pulmonary Hospital                                                                                                                                                                                                                                
  Zhou \[[@b34-ceo-2020-00570]\]    Huazhong University Hospital          Hubei                IV                  12/29/2019                    62                S, CT, L   Yes                  Yes   Yes   Yes   Yes   Yes   NA    NA    Yes   Good   
  Li \[[@b35-ceo-2020-00570]\]      Tongji Hospital                       Hubei                IV                  01/16/2020                    51                S, CT      Yes                  Yes   Yes   No    Yes   Yes   NA    CD    Yes   Good   
  Huang \[[@b36-ceo-2020-00570]\]   Zhongnan Hospital                     Hubei                IV                  01/23/2020                    34                S, CT, L   Yes                  Yes   NA    NA    Yes   Yes   No    NA    Yes   Fair   
  Outside of Wuhan                                                                                                                               289                                                                                                      
                                    Liu \[[@b37-ceo-2020-00570]\]         Xixi Hospital        Zhejiang            IV                            01/22/2020        10         S, CT, L             Yes   Yes   Yes   NA    Yes   Yes   Yes   NA    Yes    Good
  Liu \[[@b38-ceo-2020-00570]\]     Hainan Provincial People's Hospital   Hainan               IV                  01/15/2020                    56                S, CT, L   Yes                  Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes   Good   
  Zhu \[[@b39-ceo-2020-00570]\]     First Affiliated Hospital of USTC     Anhui                IV                  01/24/2020                    32                S, CT, L   Yes                  Yes   Yes   Yes   Yes   Yes   NA    NA    Yes   Good   
  Zhao \[[@b40-ceo-2020-00570]\]    Changsha Hospital                     Hunan                IV                  \-                            101               S, CT      Yes                  Yes   Yes   NA    No    Yes   NA    Yes   Yes   Fair   
  Yueyang Hospital                                                                                                                                                                                                                                        
  Changde Hospital                                                                                                                                                                                                                                        
  Xiangtan Hospital                                                                                                                                                                                                                                       
  Xu \[[@b41-ceo-2020-00570]\]      Guangzhou Eighth People's Hospital    Guangdong            IV                  01/23/2020                    90                S, CT      Yes                  Yes   Yes   NA    Yes   Yes   NA    NA    Yes   Fair   
  Total                                                                                                                                          627                                                                                                      

S, symptom; CT, chest computed tomography; L, laboratory test.

###### 

The proportions of clinical features of the included subjects

  First author       Age (range, yr)                   Sex (M:F)               No. of patients   Symptom, no. (%)                                                                                                                                                       
  ------------------ --------------------------------- ----------------------- ----------------- ------------------ ---------------- ---------------- ---------------- --------------- ---------------- --------------- --------------- --------------- --------------- ---------------
  Wuhan                                                                                                                                                                                                                                                                 
                     Zhou \[[@b33-ceo-2020-00570]\]    Median, 56.0 (46--57)   119:72            191                                 180 (94.2)       151 (79.0)       44 (23.0)                        29 (15.2)                                       16 (8.3)        44 (23.0)
                     Zhou \[[@b34-ceo-2020-00570]\]    Mean, 52.8 (30--77)     39:23             62                                  54 (87.1)        28 (45.2)                        15 (24.2)        20 (32.2)                                       9 (14.5)        14 (22.6)
                     Li \[[@b35-ceo-2020-00570]\]      Mean, 58.0 (26--83)     28:23             51                 1 (2.0)          46 (90.2)        1 (2.0)                                                                                                           3 (5.9)
                     Huang \[[@b36-ceo-2020-00570]\]   Mean, 56.0 (26--88)     14:20             34                                  32 (94.1)        17 (30)          8 (23.5)        5 (14.7)         22 (64.7)                       2 (5.9)         5 (14.7)        
                     Total                                                     200:138           338                1/51 (2.0)       312/338 (92)     197/338 (58.3)   52/225 (23.1)   20/96 (20.8)     71/287 (24.7)                   2/34 (5.9)      30/287 (10.5)   61/304 (20.1)
  Outside of Wuhan                                                                                                                                                                                                                                                      
                     Liu \[[@b37-ceo-2020-00570]\]     Median, 42 (34--50)     4:6               10                                  7 (70.0)         8 (80.0)                                                          4 (40.0)        3 (30.0)        3 (30.0)        
                     Liu \[[@b38-ceo-2020-00570]\]     NA                      31:25             56                                  44 (78.6)        21 (37.5)                        4 (7.1)                                                          10 (17.9)       5 (8.9)
                     Zhu \[[@b39-ceo-2020-00570]\]     Median, 46 (35--52)     15:17             32                                  27 (84.4)        21 (66.6)        5 (15.6)                         5 (15.6)                        1 (3.1)         1 (3.1)         
                     Zhao \[[@b40-ceo-2020-00570]\]    Mean, 44.44 (17--75)    56:45             101                2 (2.1)          79 (78.2)        63 (62.4)                        1 (1.0)          17 (16.8)       12 (11.9)                       5 (5.0)         
                     Xu \[[@b41-ceo-2020-00570]\]      Median, 50 (18--86)     39:51             90                 6 (6.7)          70 (77.8)        57 (63.3)        11 (12.2)                        25 (27.8)       23 (25.6)       4 (4.4)         12 (13.3)       19 (21.1)
                     Total                                                     145:144           289                8/191 (4.2)      227/289 (78.5)   170/289 (58.8)   16/122 (13.1)   5/157 (6.3)      47/223 (21.1)   39/201 (19.4)   8/132 (6.1)     31/289 (10.7)   24/146 (16.4)
  Total                                                345:282                 627               9/242 (4.1)        539/627 (86.0)   367/627 (58.5)   68/347 (19.6)    25/253 (9.9)    118/510 (22.9)   39/201 (19.4)   10/166 (6.0)    61/576 (10.6)   85/450 (18.9)   

GI, gastrointestinal; NA, not applicable.

###### 

The proportions of pathologic patterns and their distributions on chest computed tomography of the included subjects

  First author                       No. of patients   Pathologic pattern   Distribution                                      
  ---------------------------------- ----------------- -------------------- ---------------- --------------- ---------------- ----------------
  Wuhan                                                                                                                       
   Zhou \[[@b33-ceo-2020-00570]\]    191               136 (71.2)           112 (58.6)                                        143 (74.8)
   Zhou \[[@b34-ceo-2020-00570]\]    62                25 (40.3)            21 (33.8)        10 (16.1)       52 (83.8)        52 (83.9)
   Li \[[@b35-ceo-2020-00570]\]      51                46 (90.2)            21 (41.1)        3 (5.9)         48 (94.1)        48 (94.1)
   Huang \[[@b36-ceo-2020-00570]\]   34                                                      3 (8.8)                          27 (79.4)
   Total                             338               207/304 (68.1)       154/304 (50.6)   16/147 (10.8)   100/113 (88.5)   270/338 (79.9)
  Outside of Wuhan                                                                                                            
   Liu \[[@b37-ceo-2020-00570]\]     10                4 (40.0)             5 (50.0)                                          
   Liu \[[@b38-ceo-2020-00570]\]     56                                                      34 (60.7)       40 (71.4)        
   Zhu \[[@b39-ceo-2020-00570]\]     32                15 (46.9)            4 (12.5)         1 (3.1)         29 (90.6)        29 (90.6)
   Zhao \[[@b40-ceo-2020-00570]\]    101               87 (86.1)            44 (43.6)        6 (5.9)         87 (86.1)        83 (82.1)
   Xu \[[@b41-ceo-2020-00570]\]      90                65 (72.2)            12 (13.3)        12 (13.3)       53 (58.9)        53 (58.8)
   Total                             289               171/233 (73.3)       65/233 (27.9)    53/279 (19.0)   209/279 (74.9)   165/223 (74.0)
  Total                              627               378/537 (66.8)       219/537 (40.8)   383/561 (68)    309/392 (78.8)   435/561 (77.5)

Values are presented as number (%).

GGO, ground-glass opacity.
